We are live on ! Find out more
MC

Merck & Co Portfolio holdings

AUM $349M
1-Year Est. Return 146.07%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+146.07%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$73.2M
Cap. Flow
+$40.8M
Cap. Flow %
11.67%
Top 10 Hldgs %
99.71%
Holding
14
New
2
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EIKN
Eikon Therapeutics
EIKN
+$22.3M
2
AKTS
Aktis Oncology
AKTS
+$18.5M
3
HURA
TuHURA Biosciences
HURA
+$6.73K

Top Sells

Rank Stock Value
1
XLO icon
Xilio Therapeutics
XLO
+$8

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$117M 33.56%
2,308,190
– –
PSNL icon
2
Personalis
PSNL
$1.4B
$89.5M 25.6%
14,044,943
– –
KYMR icon
3
Kymera Therapeutics
KYMR
$8.68B
$64.3M 18.4%
772,165
– –
TRDA icon
4
Entrada Therapeutics
TRDA
$266M
$22M 6.28%
1,739,768
– –
EIKN
5
Eikon Therapeutics
EIKN
$496M
$17.6M 5.05%
+1,666,666
New +$22.3M
AKTS
6
Aktis Oncology
AKTS
$1.29B
$17M 4.88%
+952,844
New +$18.5M
ALEC icon
7
Alector
ALEC
$201M
$7.62M 2.18%
3,545,719
– –
STRO icon
8
Sutro Biopharma
STRO
$399M
$6.78M 1.94%
272,351
– –
EVAX
9
Evaxion A/S
EVAX
$25M
$4.52M 1.29%
1,214,126
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.45B
$1.83M 0.52%
93,414
– –
XLO icon
11
Xilio Therapeutics
XLO
$61M
$891K 0.26%
105,982
-1
-0% -$8
CARM
12
DELISTED
Carisma Therapeutics
CARM
$47.9K 0.01%
1,473,240
– –
NEUP
13
Neuphoria Therapeutics
NEUP
$21.2M
$40.8K 0.01%
10,027
– –
HURA
14
TuHURA Biosciences
HURA
$134M
$34.8K 0.01%
19,445
+5,495
+39% +$6.73K

Similar funds

KFG
Kingdom Financial Group Peoria, Arizona $349M AUM 12.25% 1-Year Est. Return
LAS
Lloyd Advisory Services Suwanee, Georgia $349M AUM 13.97% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
EPW
Endeavor Private Wealth Topeka, Kansas $349M AUM 16.45% 1-Year Est. Return
NC
Nokomis Capital Dallas, Texas $349M AUM 75.66% 1-Year Est. Return
1CP
11 Capital Partners Darien, Connecticut $348M AUM 19.84% 1-Year Est. Return
SMC
Spider Management Company Richmond, Virginia $351M AUM 18.35% 1-Year Est. Return
AWA
Argos Wealth Advisors Sacramento, California $348M AUM

Merck & Co's Q1 2026 Portfolio in Review

As of Q1 2026, Merck & Co held 14 positions worth $349M, up 26% from $276M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Merck & Co deployed $40.8M of net new capital in Q1 2026, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Eikon Therapeutics: 1,666,666 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Xilio Therapeutics, an estimated $8 trimmed.

  • Merck & Co's largest Q1 2026 buy was Eikon Therapeutics: 1,666,666 shares worth $17.6M.
  • Merck & Co added most to TuHURA Biosciences in Q1 2026, an estimated $6.73K increase.
  • Merck & Co's biggest Q1 2026 reduction was Xilio Therapeutics, cutting an estimated $8.
  • Merck & Co's ten largest holdings make up 100% of its $349M portfolio in Q1 2026.
  • Merck & Co opened 2 new positions and closed 0 in Q1 2026.
  • Merck & Co's portfolio value rose 26% quarter-over-quarter to $349M.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.